EGFR and cancer: These results prompted the authors to propose conjugate 27 as a potential platform for targeting translocalized mutant forms of EGFR and for the delivery of theranostic agents into cancer cells or across the blood-brain barrier (BBB) given the strong negative charge of tumoral cells and the BBB endothelial cells [88].